Evotec International GmbH
29 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Recorded under 3 name spellings.
2
Ending by 2030
Jan 2027
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Jan 11, 2027The maintenance fee for Ret Kinase Inhibitors (US 11,697,647) comes due Jan 11, 2027. Unpaid by Jul 12, 2027, it lapses early.
- 1 fee due Mar 22, 2027The maintenance fee for Sulfoximine Substituted Quinazolines for Pharmaceutical Compositions (US 9,139,577) comes due Mar 22, 2027. Unpaid by Sep 22, 2027, it lapses early.
- 1 fee due Oct 26, 2027The maintenance fee for Tissue modeling in embryonic stem (ES) cell system (US 9,321,997) comes due Oct 26, 2027. Unpaid by Apr 26, 2028, it lapses early.
Recent changes
- 1 of the patents on this record was granted since Aug 21, 2026
- Aug 25 US 12,715,865 Modulators of the Integrated Stress Response Pathway
- 3 terms have ended since Aug 21, 2026
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,318,488 | Assay for drug discovery based on in vitro differentiated cells In force · USPTO record | In force | USPTO record | |
| US 9,321,997 | Tissue modeling in embryonic stem (ES) cell system In force · USPTO record | In force | USPTO record | |
| US 9,945,840 | Non-invasive, in vitro functional tissue assay systems In force · USPTO record | In force | USPTO record | |
| US 8,901,138 | Sulfoximine Substituted Quinazolines for Pharmaceutical Compositions In force · High confidence | In force | High confidence | |
| US 9,139,577 | Sulfoximine Substituted Quinazolines for Pharmaceutical Compositions In force · High confidence | In force | High confidence | |
| US 10,167,296 | Sulfoximine Substituted Quinazolines for Pharmaceutical Compositions In force · High confidence | In force | High confidence | |
| US 12,533,356 | Pyrazolopyrimidine Compounds as Adenosine Receptor Antagonists In force · Low confidence | In force | Low confidence | |
| US 11,697,647 | Ret Kinase Inhibitors In force · High confidence | In force | High confidence | |
| US 12,258,338 | Modulators of the Integrated Stress Response Pathway In force · High confidence | In force | High confidence | |
| US 12,600,720 | Modulators of the Integrated Stress Response Pathway In force · High confidence | In force | High confidence |
Also on record, not counted in the 12: 29 patents in force now held by others · 16 lapsed for an unpaid fee · 11 ended at full term. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
6 pending · 4 abandoned · 5 no status recorded